Hematological Effects of Direct Acting Antiviral Drugs (DAAs) During and After Successful Treatment of Hepatitis C Patients with Ribavirin Free Regimen

Abstract

HCV is a major public health problem in Egypt. The standard of care for treatment of HCV has always been Peg-INF and Ribavirin for 24 weeks, depending on virological response. DAAs, a new era of treatment started in December 2013 with approval of Sofosbovir by FDA, followed by many others. The aim of this study was to evaluate the hematological effects of DAAs in patients receiving Ribavirin free regimens to assess the beneficial or the adverse effects of these medications. The study was conducted on 120 patients with chronic HCV who were child A according to Child-Pugh score, receiving SOF/SIM or SOF/DAC for 12 weeks. All patients were subjected to history taking, clinical examination and pretreatment assessment including laboratory evaluation with CBC, Liver enzymes, Liver functions at baseline, after 4 weeks, 12 weeks and 24 weeks.Patients were classified into 2 groups according to treatment regimen into:Group A: Patients receiving SOF/SIM regimen and Group B: Patients receiving SOF/DAC regimen